Mochida Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Naoyuki Mochida
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 26yrs |
| CEO ownership | 3.0% |
| Management average tenure | 7yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Mochida Pharmaceutical (TSE:4534) Is Due To Pay A Dividend Of ¥40.00
Dec 04
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Sep 06Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Aug 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Aug 08Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Jul 25Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Jul 11Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Mar 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Mar 02CEO
Naoyuki Mochida (66 yo)
26yrs
Tenure
Mr. Naoyuki Mochida is President of Mochida Pharmaceutical Co., Ltd. from January 1999 and serves as its Representative Director since January 1999 and serves as its Chairperson. Mr. Mochida joined the Moc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chairperson | 26yrs | no data | 3.02% ¥ 3.6b | |
| Executive Officer and Legal & Compliance Manager | no data | no data | no data | |
| Executive Officer. Deputy GM of Corporate Planning & Mang. Div. and Head of Human Resources Dept. | no data | no data | no data | |
| Senior Executive MD & Director | no data | no data | no data | |
| Senior EVP & Representative Director | no data | no data | 0.042% ¥ 49.2m | |
| Senior Executive MD & Director | no data | no data | 0.029% ¥ 34.6m | |
| Executive Managing Officer Executive Director | no data | no data | 0.017% ¥ 19.6m | |
| Managing Executive Officer & Head of Business Development Division | no data | no data | no data | |
| Managing Executive Officer & GM of Medical Device Product Development | 7yrs | no data | no data | |
| GM of Pharmaceutical Development Division & Managing Executive Officer | no data | no data | no data | |
| Executive Managing Officer | 2.6yrs | no data | no data | |
| Executive Officer & Head of Pharmaceutical Business Division | no data | no data | no data |
7.0yrs
Average Tenure
65yo
Average Age
Experienced Management: 4534's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chairperson | 26yrs | no data | 3.02% ¥ 3.6b | |
| Senior Executive MD & Director | 14.6yrs | no data | no data | |
| Senior EVP & Representative Director | 13.6yrs | no data | 0.042% ¥ 49.2m | |
| Senior Executive MD & Director | 10.6yrs | no data | 0.029% ¥ 34.6m | |
| Executive Managing Officer Executive Director | 5.6yrs | no data | 0.017% ¥ 19.6m | |
| Senior Managing Executive Officer & Director | 1.6yrs | no data | 0.0017% ¥ 2.0m | |
| Executive Managing Officer & Director | less than a year | no data | no data | |
| Independent Outside Director | 12.6yrs | no data | 0.010% ¥ 12.3m | |
| Full-Time Audit & Supervisory Board Member | 1.6yrs | no data | 0.012% ¥ 14.3m | |
| Independent Outside Director | 2.6yrs | no data | 0.0014% ¥ 1.7m | |
| Independent Outside Director | 1.6yrs | no data | 0.00085% ¥ 1.0m | |
| Independent Outside Director | less than a year | no data | no data |
4.1yrs
Average Tenure
64.5yo
Average Age
Experienced Board: 4534's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 13:20 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mochida Pharmaceutical Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiyuki Hibino | Mitsubishi UFJ Morgan Stanley Securities Company Limited |
| Taku Ouchi | SMBC NIKKO |
| Jayaprabha Dhavale | Virtua Research Inc. |